Publikationen in Zusammenarbeit mit Forschern von University of Turin (17)

2024

  1. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

    Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737

  2. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. Surgical Treatment of Nonmineralized Supraspinatus Tendinopathy in Dogs: A Retrospective Long-Term Follow-Up

    Animals, Vol. 13, Núm. 4

2022

  1. Providing Spiritual Care to In-Hospital Patients During COVID-19: A Preliminary European Fact-Finding Study

    Journal of Religion and Health, Vol. 61, Núm. 3, pp. 2212-2232

2021

  1. Haplo-identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMT

    American Journal of Hematology, Vol. 96, Núm. 5, pp. 571-579

2020

  1. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 3, pp. 628-639

2017

  1. Early postnatal genistein administration permanently affects nitrergic and vasopressinergic systems in a sex-specific way

    Neuroscience, Vol. 346, pp. 203-215

2016

  1. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 6, pp. 471-478

2014

  1. Perinatal exposure to genistein affects the normal development of anxiety and aggressive behaviors and nitric oxide system in CD1 male mice

    Physiology and Behavior, Vol. 133, pp. 107-114

2012

  1. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting

    Therapeutic Drug Monitoring, Vol. 34, Núm. 2, pp. 232-235

2011

  1. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction

    Journal of Infectious Diseases, Vol. 204, Núm. 1, pp. 145-153

  2. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: The ARTEN Trial

    Antiviral Therapy, Vol. 16, Núm. 3, pp. 339-348

  3. The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference

    Journal of Viral Hepatitis, Vol. 18, Núm. SUPPL. 1, pp. 1-16

2010

  1. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations

    AIDS, Vol. 24, Núm. 7, pp. 1064-1066

  2. Population pharmacokinetic modeling of the association between 63396C→T pregnane X receptor polymorphism and unboosted atazanavir clearance

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 12, pp. 5242-5250

2009

  1. When and how to use maraviroc in HIV-infected patients

    AIDS, Vol. 23, Núm. 18, pp. 2377-2385

2005

  1. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations

    AIDS Research and Human Retroviruses, Vol. 21, Núm. 6, pp. 555-559